CoChat

Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health

Open access
Rodriguez, Daniel, Lavie, Carl J., Elagizi, Andrew, Milani, Richard V. · 2022 · Nutrients

The DOI matches its Crossref record; 66 of the 94 references it cites were found in a registry or an index, and 26 are not checked yet; 13 of the 82 sources its claims cite were checked for support.

Abstract

Twenty percent of deaths in the United States are secondary to cardiovascular diseases (CVD). In patients with hyperlipidemia and hypertriglyceridemia, studies have shown high atherosclerotic CVD (ASCVD) event rates despite the use of statins. Given the association of high triglyceride (TG) levels with elevated cholesterol and low levels of high-density lipoprotein cholesterol, the American Heart Association (AHA)/American College of Cardiology (ACC) cholesterol guidelines recommend using elevated TGs as a “risk-enhancing factor” for ASCVD and using omega 3 fatty acids (Ω3FAs) for patients with persistently elevated severe hypertriglyceridemia. Ω3FA, or fish oils (FOs), have been shown to reduce very high TG levels, hospitalizations, and CVD mortality in randomized controlled trials (RCTs). We have published the largest meta-analysis to date demonstrating significant effects on several CVD outcomes, especially fatal myocardial infarctions (MIs) and total MIs. Despite the most intensive research on Ω3FAs on CVD, their benefits have been demonstrated to cluster across multiple systems and pathologies, including autoimmune diseases, infectious diseases, chronic kidney disease, central nervous system diseases, and, most recently, the COVID-19 pandemic. A review and summary of the controversies surrounding Ω3FAs, some of the latest evidence-based findings, and the current and most updated recommendations on Ω3FAs are presented in this paper.

Verified 2026-10-05 · 26 references not checked yet

Overview

CoChat Summary

TL;DR

This review summarizes evidence and controversies on omega-3 polyunsaturated fatty acids (Ω3FAs) for cardiovascular health, covering mechanisms, dietary sources, the omega-3 index, and recent randomized and meta-analytic data. It concludes that higher-dose EPA/DHA may reduce major cardiovascular outcomes, especially myocardial infarction, and recommends 2 g/d EPA/DHA generally and 4 g/d for patients with ASCVD and hypertriglyceridemia.

Key findings

  • In REDUCE-IT, 8,179 statin-treated patients with fasting triglycerides 135–499 mg/dL and LDL cholesterol 41–100 mg/dL received 2 g icosapent ethyl twice daily or placebo over 4.9 years; the primary composite endpoint occurred in 17.2% vs. 22.0% (HR 0.75; 95% CI 0.68–0.83; p < 0.001), and the secondary composite of CVD death, non-fatal MI, or non-fatal stroke occurred in 11.2% vs. 14.8% (HR 0.74; 95% CI 0.65–0.83; p < 0.001).
  • A meta-analysis of 13 RCTs with 127,477 participants found marine Ω3 supplementation associated with lower MI (RR 0.92; 95% CI 0.86–0.99; p = 0.020), CHD death (RR 0.92; 95% CI 0.86–0.98; p = 0.014), total CHD (RR 0.95; 95% CI 0.91–0.99; p = 0.008), CVD death (RR 0.93; 95% CI 0.88–0.99; p = 0.013), and total CVD (RR 0.97; 95% CI 0.94–0.99; p = 0.015), even when excluding REDUCE-IT.
  • An earlier meta-regression of 40 interventional trials with 135,267 participants found each 1 g/day increase in Ω3 associated with a 5.8% reduction in CVD events and a 9.0% reduction in MIs; the authors’ updated meta-analysis of 42 trials with nearly 150,000 participants found each 1 g/d increase in DHA and EPA associated with a 9% reduction in MI but no reduction in CVD events.
  • The omega-3 index (O3I) of 8% was associated with decreased CHD mortality risk, while an O3I below 4% increased this risk; the AHA recommends 3 ounces of cooked fish twice weekly, yet NHANES reported a 6.8% decrease in Americans older than 20 consuming seafood more than once weekly between 2005–2006 and 2015–2016.

Methods

  • Narrative review/update summarizing fundamentals, controversies, and current recommendations for Ω3FAs in cardiovascular and routine clinical practice, including dietary sources, molecular mechanisms, the omega-3 index, recent data, dosage, chronic kidney disease, heart failure, brain effects, and COVID-19.
  • Evidence discussed includes RCTs (e.g., DART, GISSI-Prevenzione, OMEGA, REDUCE-IT, VITAL, JELIS, STRENGTH, GISSI-HF), meta-analyses/meta-regressions (10 trials with 77,917 participants; 13 RCTs with 127,477 participants; 40 trials with 135,267 participants; updated 42 trials with nearly 150,000 participants; 21 RCTs plus 1 observational study with 2,277 participants), and observational analyses (NHANES, MESA, MERLIN-TIMI 36, CKD cohort).
  • Main analysis is a narrative synthesis of selected trial and meta-analysis results; no new primary data collection or formal systematic review methods are reported.

Limitations

  • The paper states that studies surrounding Ω3FAs remain controversial, individual trial results are inconsistent, and heterogeneity may arise from differences in dosages, follow-up duration, sample sizes, and lower event rates; further RCTs are necessary.
  • The paper notes specific limitations of cited studies: the OMEGA trial lacked statistical power and had reduced rates of SCD, total mortality, and MACE after one year; the COVID-19 O3I pilot study was underpowered and did not reach statistical significance.
  • Evident from the text: this is a narrative review rather than a systematic review or meta-analysis, with no formal search strategy, inclusion criteria, risk-of-bias assessment, or quantitative pooling reported.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/nu14235146

Cites

66 of 92 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Alpha-linolenic acid (ALA) as a substrate of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Figure 1 Alpha-linolenic acid (ALA) as a substrate of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).CC BY · PubMed Central
Figure 2 Percentage of adults aged 20 and over consuming seafood at least two times per week, by age and sex, in the United States in 2013–2016 [23].
Figure 2 Percentage of adults aged 20 and over consuming seafood at least two times per week, by age and sex, in the United States in 2013–2016 [23].CC BY · PubMed Central
Figure 3 REDUCE-IT trial prespecified endpoints. The rates of all endpoints, except death from any cause, were significantly lower in icosapent ethyl (eicosapentaenoic acid ethyl esters). Data were adapted from NEJM [5] and reproduced with Mayo Clinic Proc [57] permission.
Figure 3 REDUCE-IT trial prespecified endpoints. The rates of all endpoints, except death from any cause, were significantly lower in icosapent ethyl (eicosapentaenoic acid ethyl esters). Data were adapted from NEJM [5] and reproduced with Mayo Clinic Proc [57] permission.CC BY · PubMed Central
Figure 4 Pooled results from a meta-analysis. Pooled estimate of relative risk and 95% confidence interval, number of studies, and the combined number of participants. CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction [52].
Figure 4 Pooled results from a meta-analysis. Pooled estimate of relative risk and 95% confidence interval, number of studies, and the combined number of participants. CHD, coronary heart disease; CVD, cardiovascular disease; MI, myocardial infarction [52].CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 0 Not valid · 56 Not checked · 13 Own results and interpretations

35 more claims · 3 with their cited sources checked

Create a free account to see all 80 claims and to verify the 69 references still open.

See all claims — free account
  • It may state two separate claims as one. 37
  • Probably not a substantial claim. 3
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Cited by

See all 84

Metadata

Authors
Rodriguez, D., Lavie, C. J., Elagizi, A., & Milani, R. V.
Affiliations
  • John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Ochsner Clinical School—The University of Queensland School of Medicine, New Orleans, LA 70121, USA
  • Ochsner Health System (US)
Corresponding author
Lavie, Carl J.
Venue
Nutrients
Publisher
MDPI AG
Published
2022-12-03
Volume
14
Issue
23
Pages
5146
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4310682235
Cited by
81
References
94
Citations by year
2026: 10 · 2025: 22 · 2024: 23 · 2023: 26
FWCI
2.39
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
omega-3 polyunsaturated fatty acids, fish oil, cardiovascular disease, hypertriglyceridemia, atherosclerotic cardiovascular disease, triglycerides, myocardial infarction, statin therapy, hyperlipidemia, cardiovascular mortality, autoimmune disease, chronic kidney disease, central nervous system disorders, COVID-19 pandemic
MeSH terms
COVID-19, Cardiovascular Diseases, Cholesterol, Humans, Hyperlipidemias, Cholesterol, HDL, Myocardial Infarction, Triglycerides, United States, Hypertriglyceridemia, Fatty Acids, Omega-3, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.